The ER+/luminal A subtype is the most common subtype of breast cancer and its current treatment strategies include endocrine therapy and targeted therapy along with chemotherapy and radiotherapy, or with CDK4/6 inhibitors at an advanced stage [20]. Here, ESR1 is linked to breast carcinoma.